Impact of secondary lymphedema after head and neck cancer treatment on symptoms, functional status, and quality of life

Head and Neck

Volumn 35, Issue 7, 2013, Pages 1026-1035

  Deng, Jie ^a   Murphy, Barbara A ^b   Dietrich, Mary S ^a,b,c   Wells, Nancy ^a   Wallston, Kenneth A ^a   Sinard, Robert J ^b   Cmelak, Anthony J ^b   Gilbert, Jill ^b   Ridner, Sheila H ^a,b  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

functional status; head and neck cancer; lymphedema; quality of life (QOL); symptom

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BODY IMAGE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; DISEASE SEVERITY; FEMALE; FUNCTIONAL STATUS; HEAD AND NECK CANCER; HEARING ACUITY; HUMAN; LYMPHEDEMA; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTIMODALITY CANCER THERAPY; NECK; PHYSICAL MOBILITY; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; RANGE OF MOTION; SYMPTOMATOLOGY; TRISMUS;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; LYMPHEDEMA; MALE; MIDDLE AGED; NEOPLASM STAGING; POSTOPERATIVE COMPLICATIONS; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; SICKNESS IMPACT PROFILE;

EID: 84879415664     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23084     Document Type: Article

References (49)

1. Vokes EE, Kies MS, Haraf DJ, et al. Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. J Clin Oncol 2000; 18: 1652-1661.
2. Földi M, Földi E, Strobenreuther RHK, et al. Földi's textbook of lymphology, 2nd ed. München, Germany, Urban & Fischer; 2006.
3. Lymphoedema Framework. Best practice for the management of lymphoedema. International Consensus. London: MEP Ltd; 2006.
4. Büntzel J, Glatzel M, Mücke R, Micke O, Bruns F,. Influence of amifostine on late radiation-toxicity in head and neck cancer-a follow-up study. Anticancer Res 2007; 27: 1953-1956.
5. Dietz A, Rudat V, Nollert J, Helbig M, Vanselow B, Weidauer H,. Chronic laryngeal edema as a late reaction to radiochemotherapy. [Article in German]. HNO 1998; 46: 731-738.
6. Schiefke F, Akdemir M, Weber A, Akdemir D, Singer S, Frerich B,. Function, postoperative morbidity, and quality of life after cervical sentinel node biopsy and after selective neck dissection. Head Neck 2009; 31: 503-512.
7. Wolff HA, Overbeck T, Roedel RM, et al. Toxicity of daily low dose cisplatin in radiochemotherapy for locally advanced head and neck cancer. J Cancer Res Clin Oncol 2009; 135: 961-967.
8. Hammond T., The treatment of head and neck lymphedema, 04/12 update. http://www.lymphnotes.com/article.php/id/378/.
9. Zimmermann T, Leonhardt H, Kersting S, Albrecht S, Range U, Eckelt U,. Reduction of postoperative lymphedema after oral tumor surgery with sodium selenite. Biol Trace Elem Res 2005; 106: 193-203.
10. Bruns F, Büntzel J, Mücke R, Schönekaes K, Kisters K, Micke O,. Selenium in the treatment of head and neck lymphedema. Med Princ Pract 2004; 13: 185-190.
11. Micke O, Bruns F, Mücke R, et al. Selenium in the treatment of radiation-associated secondary lymphedema. Int J Radiat Oncol Biol Phys 2003; 56: 40-49.
12. Földi M, Földi E, Kubik S,. Textbook of Lymphology. München, Germany: Urban & Fischer; 2003.
13. Patterson JM, Hildreth A, Wilson JA,. Measuring edema in irradiated head and neck cancer patients. Ann Otol Rhinol Laryngol 2007; 116: 559-564.
14. Murphy BA, Wells NL, Cmelak AJ, Netterville JL, Burkey BB, Smith KZ,. Reliability and validity for the Vanderbilt Head and Neck Symptom Survey (VHNSS): a new tool to assess symptom burden in patients undergoing chemoradiation. 2004 ASCO Annual Meeting Proceedings. J Clin Oncol 2004; 22: 14s (abstract 5569).
15. Murphy BA, Dietrich MS, Wells N, et al. Reliability and validity of the Vanderbilt Head and Neck Symptom Survey: a tool to assess symptom burden in patients treated with chemoradiation. Head Neck 2010; 32: 26-37.
16. Bjelland I, Dahl AA, Haug TT, Neckelmann D,. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res 2002; 52: 69-77.
17. Razavi D, Delvaux N, Bredart A, et al. Screening for psychiatric disorders in a lymphoma out-patient population. Eur J Cancer 1992; 28A: 1869-1872.
18. Zigmond AS, Snaith RP,. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361-370.
19. Moorey S, Greer S, Watson M, et al. The factor structure and factor stability of the hospital anxiety and depression scale in patients with cancer. Br J Psychiatry 1991; 158: 255-259.
20. Cash TF, Pruzinsky T,. Body image: a handbook of theory research and clinical practice. New York: Guilford Press; 2002.
21. Hopwood P, Fletcher I, Lee A, Al Ghazal S,. A body image scale for use with cancer patients. Eur J Cancer 2001; 37: 189-197.
22. Reynolds J, Marsh D, Koller H, Zenenr J, Bannister G,. Cervical range of movement in relation to neck dimension. Eur Spine J 2009; 18: 863-868.
23. Williams MA, McCarthy CJ, Chorti A, Cooke MW, Gates S,. A systematic review of reliability and validity studies of methods for measuring active and passive cervical range of motion. J Manipulative Physiol Ther 2010; 33: 138-155.
24. Common Terminology Criteria for Adverse Events, Version 3.0 (CTCAE v3.0), 8/06 update. http://ctep.cancer.gov/protocolDevelopment/electronic- applications/docs/ctcaev3.pdf.
25. Fix JD,. Neuroanatomy (3rd ed). Philadelphia: Lippincott Williams & Wilkins; 2002.
26. Pirozzo S, Papinczak T, Glasziou P,. Whispered voice test for screening for hearing impairment in adults and children: systematic review. BMJ 2003; 327: 967.
27. List MA, D'Antonio LL, Cella DF, et al. The performance status scale for head and neck cancer patients and the functional assessment of cancer therapy-head and neck scale. A study of utility and validity. Cancer 1996; 77: 2294-2301.
28. Eisbruch A, Schwartz M, Rasch C, et al. Dysphagia and aspiration after chemoradiotherapy for head-and-neck cancer: which anatomic structures are affected and can they be spared by IMRT? Int J Radiat Oncol Biol Phys 2004; 60: 1425-1439.
29. Machtay M, Moughan J, Trotti A, et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 2008; 26: 3582-3589.
30. Piso DU, Eckardt A, Liebermann A, Gutenbrunner C, Schäfer P, Gehrke A,. Early rehabilitation of head-neck edema after curative surgery for orofacial tumors. Am J Phys Med Rehabil 2001; 80: 261-269.
31. Manikantan K, Khode S, Sayed SI, et al. Dysphagia in head and neck cancer. Cancer Treat Rev 2009; 35: 724-732.
32. Murphy BA, Gilbert J,. Dysphagia in head and neck cancer patients treated with radiation: assessment, sequelae, and rehabilitation. Semin Radiat Oncol 2009; 19: 35-42.
33. MacDonald N,. Cancer cachexia and targeting chronic inflammation: a unified approach to cancer treatment and palliative/supportive care. J Support Oncol 2007; 5: 157-162; discussion 164-166.
34. Delano MJ, Moldawer LL,. The origins of cachexia in acute and chronic inflammatory diseases. Nutr Clin Pract 2006; 21: 68-81.
35. Verdonck-de Leeuw IM, Keus RB, Hilgers FJ, et al. Consequences of voice impairment in daily life for patients following radiotherapy for early glottic cancer: voice quality, vocal function, and vocal performance. Int J Radiat Oncol Biol Phys 1999; 44: 1071-1078.
36. Murphy BA, Gilbert J, Ridner SH,. Systemic and global toxicities of head and neck treatment. Expert Rev Anticancer Ther 2007; 7: 1043-1053.
37. Ridner SH,. Lymphedema of the head and neck: an overview. National Lymphedema Network Lymph Link 2008; 20: 1-3.
38. Smith BG, Lewin JS,. Lymphedema management in head and neck cancer. Curr Opin Otolaryngol Head Neck Surg 2010; 18: 153-158.
39. Jäger G, Döller W, Roth R,. Quality-of-life and body image impairments in patients with lymphedema. Lymphology 2006; 39: 193-200.
40. Morgan PA, Franks PJ, Moffatt CJ,. Health-related quality of life with lymphoedema: a review of the literature. Int Wound J 2005; 2: 47-62.
41. Ridner SH,. Quality of life and a symptom cluster associated with breast cancer treatment-related lymphedema. Support Care Cancer 2005; 13: 904-911.
42. Speck RM, Gross CR, Hormes JM, et al. Changes in the Body Image and Relationship Scale following a one-year strength training trial for breast cancer survivors with or at risk for lymphedema. Breast Cancer Res Treat 2010; 121: 421-430.
43. Heppner PP, Tierney CG, Wang YW, et al. Breast cancer survivors coping with lymphedema: what all counselors need to know. J Couns Dev 2009; 87: 327-338.
44. Meeske KA, Sullivan-Halley J, Smith AW, et al. Risk factors for arm lymphedema following breast cancer diagnosis in black women and white women. Breast Cancer Res Treat 2009; 113: 383-391.
45. Ridner SH,. The psycho-social impact of lymphedema. Lymphat Res Biol 2009; 7: 109-112.
46. Hsin CH, Chen TH, Young YH, Liu WS,. Comparison of otologic complications between intensity-modulated and two-dimensional radiotherapies in nasopharyngeal carcinoma patients. Otolaryngol Head Neck Surg 2010; 143: 662-668.
47. Liang KL, Su MC, Twu CW, Jiang RS, Lin JC, Shiao JY,. Long-term result of management of otitis media with effusion in patients with post-irradiated nasopharyngeal carcinoma. Eur Arch Otorhinolaryngol 2011; 268: 213-217.
48. Schultz C, Goffi-Gomez MV, Pecora Liberman PH, Pellizzon AC, Carvalho AL,. Hearing loss and complaint in patients with head and neck cancer treated with radiotherapy. Arch Otolaryngol Head Neck Surg 2010; 136: 1065-1069.
49. Armer JM, Radina ME, Porock D, Culbertson SD,. Predicting breast cancer-related lymphedema using self-reported symptoms. Nurs Res 2003; 52: 370-379.